{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:43Z","timestamp":1790889943036,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaccao.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:54:27Z","timestamp":1758081267000},"page":"781-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiovascular and Oncologic Considerations in Adult Hodgkin Lymphoma"],"prefix":"10.1016","volume":"7","author":[{"given":"Hari S.","family":"Raman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7371-5742","authenticated-orcid":false,"given":"Joshua","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-1118","authenticated-orcid":false,"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenica N.","family":"Upshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2025.07.011_bib1","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2025.07.011_bib2","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/cncr.34375","article-title":"Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors","volume":"128","author":"Lu","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2025.07.011_bib3","first-page":"1811","article-title":"Contiguity and progression in Hodgkin\u2019s disease","volume":"31","author":"Kaplan","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2025.07.011_bib4","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib5","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions","volume":"24","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib6","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin\u2019s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib7","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1998.16.3.818","article-title":"Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin\u2019s disease. International Database on Hodgkin\u2019s Disease Overview Study Group","volume":"16","author":"Loeffler","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.07.011_bib10","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1093\/annonc\/mdt389","article-title":"An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma","volume":"24","author":"Hay","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11936-019-0737-0","article-title":"Cardiovascular complications associated with mediastinal radiation","volume":"21","author":"Lee Chuy","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2025.07.011_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study","volume":"99","author":"Swerdlow","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaccao.2025.07.011_bib13","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin\u2019s lymphoma: a question of field size","volume":"26","author":"Campbell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jaccao.2021.06.007","article-title":"Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification","volume":"3","author":"Bergom","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1259\/bjr\/86221320","article-title":"The physical basis and future of radiation therapy","volume":"84","author":"Bortfeld","year":"2011","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2021.07.1716","article-title":"Radiation therapy across pediatric hodgkin lymphoma research group protocols: a report from the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) group","volume":"112","author":"Hall","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaccao.2025.07.011_bib17","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.22.00947","article-title":"Positron emission tomography-adapted therapy in bulky stage I\/II classic Hodgkin lymphoma: CALGB 50801 (Alliance)","volume":"41","author":"LaCasce","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib20","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.07.011_bib21","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib22","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1182\/blood-2023-189652","article-title":"AHOD2131: a randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma","volume":"142","author":"Henderson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2023-172574","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C)","volume":"142","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin\u2019s disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.07.011_bib27","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2025.07.011_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2025.07.011_bib29","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.07.011_bib30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12254-024-00990-w","article-title":"Advanced stage Hodgkin\u2019s lymphoma 2024\u2014update on first line treatment","volume":"17","author":"Lehner","year":"2024","journal-title":"Magazine Eur Med Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib31","article-title":"Doxorubicin-induced cardiotoxicity and risk factors","volume":"50","author":"Belger","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jaccao.2025.07.011_bib32","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.22.02423","article-title":"Dexrazoxane and long-term heart function in survivors of childhood cancer","volume":"41","author":"Chow","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib33","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.20.00264","article-title":"Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000-2016","volume":"38","author":"Dores","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51062","article-title":"Late cardiac toxic effects associated with treatment protocols for Hodgkin lymphoma in children","volume":"7","author":"Lo","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.jaccao.2025.07.011_bib35","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.3390\/ijms24076272","article-title":"Radiation treatment mechanisms of cardiotoxicity: a systematic review","volume":"24","author":"Siaravas","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaccao.2025.07.011_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib37","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.jaccao.2025.07.011_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaccao.2025.07.011_bib39","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib40","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2014.56.1373","article-title":"Individual prediction of heart failure among childhood cancer survivors","volume":"33","author":"Chow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2017.74.8673","article-title":"Prediction of ischemic heart disease and stroke in survivors of childhood cancer","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib42","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ijrobp.2017.03.026","article-title":"Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction","volume":"98","author":"Hahn","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaccao.2025.07.011_bib43","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.22.02320","article-title":"Cardiac substructure radiation dose and risk of late cardiac disease in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"41","author":"Bates","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk","volume":"92","author":"Filippi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaccao.2025.07.011_bib45","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaccao.2025.07.011_bib46","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdx287","article-title":"Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma","volume":"28","author":"Hoppe","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaccao.2025.07.011_bib48","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/joim.20028","article-title":"Association among major adverse cardiovascular events with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"297","author":"Li","year":"2025","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaccao.2025.07.011_bib50","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaccao.2025.07.011_bib51","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2025.07.011_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-208412","article-title":"Potential delayed immune-related adverse events in patients treated with frontline pembrolizumab + AVD for classic Hodgkin lymphoma","volume":"144","author":"Kuczmarski","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djz108","article-title":"Traditional cardiovascular risk factors and individual prediction of cardiovascular events in childhood cancer survivors","volume":"112","author":"Chen","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jaccao.2025.07.011_bib54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO.21.02613","article-title":"Development and validation of risk prediction models for coronary heart disease and heart failure after treatment for Hodgkin lymphoma","volume":"41","author":"de Vries","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaccao.2024.02.003","article-title":"Impact of preexisting heart failure on treatment and outcomes in older patients with Hodgkin lymphoma","volume":"6","author":"Upshaw","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib56","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2025.07.011_bib57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JOP.2016.018770","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary","volume":"13","author":"Armenian","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.jaccao.2025.07.011_bib58","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib59","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2025.07.011_bib60","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13105-013-0240-0","article-title":"Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice","volume":"69","author":"Ramanjaneyulu","year":"2013","journal-title":"J Physiol Biochem"},{"key":"10.1016\/j.jaccao.2025.07.011_bib61","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jaccao.2025.07.011_bib62","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaccao.2025.07.011_bib63","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jaccao.2025.07.011_bib64","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/1471-2407-14-842","article-title":"Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms","volume":"14","author":"Deng","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaccao.2025.07.011_bib65","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaccao.2025.07.011_bib67","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib68","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/pbc.24279","article-title":"Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children\u2019s Oncology Group","volume":"59","author":"Tebbi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaccao.2025.07.011_bib69","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib70","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ejca.2011.03.022","article-title":"The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium","volume":"47","author":"Vrooman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2025.07.011_bib71","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"Asselin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib72","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.33974","article-title":"Late health outcomes after dexrazoxane treatment: a report from the Children\u2019s Oncology Group","volume":"128","author":"Chow","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2025.07.011_bib73","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2014.59.4473","article-title":"Late mortality after dexrazoxane treatment: a report from the Children\u2019s Oncology Group","volume":"33","author":"Chow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133569","article-title":"Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials","volume":"10","author":"Xing","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaccao.2025.07.011_bib76","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib77","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1097-0142(19910915)68:6<1221::AID-CNCR2820680607>3.0.CO;2-R","article-title":"A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors","volume":"68","author":"Casper","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2025.07.011_bib78","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","article-title":"Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation","volume":"65","author":"Shapira","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2025.07.011_bib79","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1542\/peds.2012-0727","article-title":"Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes","volume":"130","author":"Lipshultz","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaccao.2025.07.011_bib80","first-page":"1","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jaccao.2025.07.011_bib81","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2025.07.011_bib82","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib83","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","article-title":"Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity","volume":"69","author":"Nabati","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib84","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib85","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib86","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2025.07.011_bib87","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.cardfail.2022.02.009","article-title":"2022 American College of Cardiology\/American Heart Association\/Heart Failure Society of America guideline for the management of heart failure: executive summary","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.jaccao.2025.07.011_bib88","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life\u2019s Essential 8: updating and enhancing the American Heart Association\u2019s construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2025.07.011_bib89","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2015.11.034","article-title":"Exercise at the extremes: the amount of exercise to reduce cardiovascular events","volume":"67","author":"Eijsvogels","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib90","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12966-022-01357-2","article-title":"Physical activity from young adulthood to middle age and premature cardiovascular disease events: a 30-year population-based cohort study","volume":"19","author":"Nagata","year":"2022","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.jaccao.2025.07.011_bib91","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/eurheartj\/ehac747","article-title":"Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis","volume":"44","author":"Dibben","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2025.07.011_bib92","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.2009.454","article-title":"Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial","volume":"301","author":"O\u2019Connor","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2025.07.011_bib93","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.020804","article-title":"Exercise-based cardiac rehabilitation and all-cause mortality among patients with atrial fibrillation","volume":"10","author":"Buckley","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2025.07.011_bib94","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2014.56.7511","article-title":"Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study","volume":"32","author":"Jones","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib95","doi-asserted-by":"crossref","first-page":"H1462","DOI":"10.1152\/ajpheart.00132.2024","article-title":"Aerobic exercise training combined with local strength exercise restores muscle blood flow and maximal aerobic capacity in long-term Hodgkin lymphoma survivors","volume":"326","author":"Santos","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib96","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1200\/JCO.2008.20.0634","article-title":"Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients","volume":"27","author":"Courneya","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2024.107645","article-title":"Design and methods of the StepByStep randomized trial of a mobile health and social media physical activity intervention among adolescent and young adult survivors of childhood cancer: a report from the Children\u2019s Oncology Group","volume":"145","author":"Beight","year":"2024","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.jaccao.2025.07.011_bib98","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2016.05.010","article-title":"Treatment of relapsed and refractory Hodgkin lymphoma","volume":"53","author":"von Tresckow","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib99","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib101","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib102","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib103","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib104","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib105","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1200\/jco.2005.23.16_suppl.6508","volume":"23","author":"Schmitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib106","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2025.07.011_bib107","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41409-018-0265-7","article-title":"Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables","volume":"54","author":"Tay","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaccao.2025.07.011_bib108","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaccao.2025.07.011_bib109","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2023-179573","article-title":"PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed\/refractory classic Hodgkin lymphoma: results from a multicenter cohort","volume":"142","author":"Desai","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib110","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-202537","article-title":"Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib111","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.07.011_bib112","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.adro.2020.06.001","article-title":"Radiation therapy for advanced-stage Hodgkin lymphoma","volume":"5","author":"Lockney","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib113","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib114","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"Celutkiene","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2025.07.011_bib115","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib116","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/bmt.2013.58","article-title":"Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study","volume":"48","author":"Wood","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaccao.2025.07.011_bib117","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","article-title":"Prediction of cardiovascular disease among hematopoietic cell transplantation survivors","volume":"2","author":"Armenian","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2025.07.011_bib118","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","article-title":"Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation","volume":"155","author":"Chow","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaccao.2025.07.011_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65294-9","article-title":"Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample","volume":"14","author":"Krishan","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2025.07.011_bib120","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","article-title":"Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors","volume":"5","author":"Vasbinder","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib121","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.20.02401","article-title":"Atrial fibrillation in patients undergoing allogeneic hematopoietic cell transplantation","volume":"39","author":"Chang","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib122","doi-asserted-by":"crossref","first-page":"e1113","DOI":"10.1161\/CIR.0000000000001220","article-title":"Cardiovascular management of patients undergoing hematopoietic stem cell transplantation: from pretransplantation to survivorship: a scientific statement from the American Heart Association","volume":"149","author":"Hayek","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2025.07.011_bib123","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib124","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033599","article-title":"Cardiovascular risk stratification of patients undergoing hematopoietic stem cell transplantation: the CARE-BMT risk score","volume":"13","author":"Vasbinder","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2025.07.011_bib125","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2025.07.011_bib126","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009122","article-title":"Risk and temporal changes of heart failure among 5-year childhood cancer survivors: a DCOG-LATER study","volume":"8","author":"Feijen","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2025.07.011_bib127","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib128","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.07.011_bib129","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.07.011_bib130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.6004\/jnccn.2025.0028","article-title":"NCCN Guidelines\u00ae insights: survivorship, version 2.2025: featured updates to the NCCN Guidelines\u00ae","volume":"23","author":"Sanft","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jaccao.2025.07.011_bib132","series-title":"Long-term follow-up guidelines v6.0","year":"2023"},{"issue":"6","key":"10.1016\/j.jaccao.2025.07.011_bib133","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaccao.2025.05.009","article-title":"IGHG recommendations for anthracycline and anthraquinone cardiac dysfunction equivalence ratios after childhood cancer: JACC: CardioOncology expert panel","volume":"7","author":"Kouwenberg","year":"2025","journal-title":"JACC CardioOncol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325002935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325002935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T23:24:27Z","timestamp":1768605867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087325002935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":129,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666087325002935"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.07.011","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and Oncologic Considerations in Adult Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}